Renal effects of S10036 in man.
The renal hemodynamic and tubular effects of S10036 (fotemustine) were evaluated in seven patients with advanced malignancy. Initial evaluation carried out prior to treatment and repeated 1 day after the first fotemustine infusion and 7 days after the second included clinical, haematological parameters, liver-function tests, and determination of the glomerular filtration rate, renal blood flow and enzymuria. The glomerular filtration rate was 108 +/- 3.7 ml/min before treatment and remained stable after the first (117 +/- 5 ml/min) and second (124 +/- 6 ml/min) fotemustine infusions. Renal blood flow and urinary beta 2-microglobulin and N'-acetylglucosaminidase excretion were also not modified by fotemustine administration. We conclude that fotemustine does not acutely alter renal haemodynamics, nor does it have direct tubular toxicity.
Deray
G
G
Department of Nephrology, Hopital Pitié-Salpêtrière, Paris, France.
Khayat
D
D
Jacquiaud
C
C
Bizzari
J P
JP
Bourbouze
R
R
Musset
L
L
Jaudon
M C
MC
Baumelou
B
B
Jacquillat
C
C
Jacobs
C
C
D000118:Acetylglucosaminidase / Q000652:urine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007684:Kidney Tubules / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D001613:beta 2-Microglobulin / Q000652:urine
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D001613:beta 2-Microglobulin; D000118:Acetylglucosaminidase; C054368:fotemustine